



Suite 506, Level 5, 50
Clarence Street
Sydney NSW 2000
W:www.bioxyne.com



30 April 2024

REPORT FOR THE QUARTER ENDED 31 MARCH 2024

Bioxyne Limited (ASX Code: BXN) (Bioxyne or the Company) is pleased to report on its activities for the quarter ended 31 March 2024.


Highlights

- Revenue at \$1.7 million for the quarter and on target for \$10 million for FY2024
- Therapeutic Goods Administration (“TGA”) GMP audit successfully completed and GMP manufacturing licence granted
- Cash on hand 31 March 2024 \$0.75 million, with further \$2.0 million in net trade working capital.
- Capital raise post 31 March 2024 raised \$1.45 million.

Results

Group revenue for the third quarter was approximately \$1.7 million with the target for FY2024 at ~\$10 million.

Breathe Life Sciences revenue for FYQ3 was constrained by late product deliveries. This has improved in Q4 with the FY2024 revenue target as above.



Operations

The medicinal cannabis business is the key revenue driver however the quarters results were constrained by a delay in receipt of product from suppliers. Demand for prescribed cannabis dried flower and oral solution remains high in Australia.

Breathe Life Sciences (“BLS”) was awarded a Good Manufacturing Practice (“GMP”) license to manufacture medical cannabis-based products, following the TGA audit during the quarter.

This is also Australia’s first GMP license to manufacture Psilocybin and MDMA. The Company’s TGA GMP license covers parts 1 and 2, allowing it to manufacture MDMA (3,4-methylenedioxymethamphetamine) and psilocybin active pharmaceutical ingredients (“APIs”) as well as final dose form capsules for supply to authorised prescribers and approved clinical trials.

The Company was then granted an upgraded and amended wholesale licence for MDMA and Psilocybin (schedule 8) finished products by the TGA, subsequent to 31 March 2024.

The Company commenced manufacturing under its GMP licence mid-March 2024, and released 4 white label batch manufacturing runs prior to 31 March 2024. Since the commencement of manufacturing activities and prior to the end of the quarter, the Company has secured \$1.4million worth of white label manufacturing purchase orders, from customers.

Manufacturing activity is forecasted to grow significantly with multiple customers indicating the intention to place standing purchase orders for manufactured products over the next 12-month period with an estimated value to be in excess of \$4.6 million.

The investment in inventory has increased from \$995k at 30 June 2023 to \$2.1 million as at 31 March 2024. Net trade working capital including inventory at 31 March 2024 was \$2.0 million.

Corporate

The Group is continuing to review a number of opportunities to expand the delivery of its plant based products to market.

The Group had a net cash outflow for the quarter of \$0.97 million principally due to inventory holding and timing of receivables which are current and amount to \$1.6 million as at 31 March 2024.

Cash balance at the end of the quarter is \$0.75 million.

The Company paid directors \$157,000 in the quarter for salaries, superannuation and directors fees.



Post quarter end the Company raised \$1.45 million through the issue of 145 million new shares at \$0.01 per share.

This announcement has been approved for release by the Board.

For further information contact:

Sam Watson
Managing Director
Bioxyne Limited
sam@breathelifesciences.com

Guy Robertson
Chief Financial Officer
Bioxyne Limited
guy@bioxyne.com

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian-headquartered international consumer health and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and licensed manufacturer, sponsor, importer and exporter of controlled substances (S3, S4, S8) in Australia.

BLS was founded in 2018 and has quickly expanded into a multi national business focused on alternative therapeutics and investigational medicines. Our corporate head office is in Sydney, and our operations extend to licensed manufacturing, warehousing, import/export, sales and distribution centers in the Gold Coast (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

Our business model is focused on manufacture of final dose form / finished products, sales and distribution in each of the territories we serve. We work with raw materials and API suppliers in 5 continents and are a market leader in manufacturing scope and quality.

The BLS logo is derived from a Japanese Maple Leaf, symbolising health, happiness and a long life well lived. While the Japanese Maple is not a medicinal plant, our company purpose is to redefine medicine by taking a holistic approach to healthcare for a healthier and happier tomorrow.

Outside of Australia the BLS Group operates a health and wellness products and brands business focussed on naturally derived active nutraceuticals, wellness and lifestyle supplements and cannabidiol (CBD) based novel foods. It primarily operates in the UK, Europe and Japan, and engages in the following activities:

- (a) owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand – Dr Watson is an internationally recognized health, lifestyle, and prescription products brand. Dr Watson products consist of cannabis-based food supplements, lifestyle products, cosmetics, functional mushrooms and nootropics, and prescription medicines in Australia;
- (b) contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe;
- (c) white label manufacture of third-party wellness and supplements brands in Japan, UK and Europe in company-owned facilities;
- (d) research and development for third party customers; and
- (e) direct sales via online and wholesale sales of BLS-owned consumer brands, such as Dr Watson® (drwatsoncbd.com, nolcbn.com, drwatsoncbd.de)

Corporate: <https://bioxyne.com>

Australia: <https://bls.com.au>; <https://blsclinics.com.au>

International: <https://breathelifesciences.com>

Dr Watson (UK and EU only): drwatsoncbd.com; drwatsoncbd.de; nolcbn.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Bioxyne Limited

ABN

97 084 464 193

Quarter ended ("current quarter")

31 March 2024

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
1. Cash flows from operating activities		
1.1 Receipts from customers	2,506	7,182
1.2 Payments for		
(a) research and development		
(b) product manufacturing and operating costs	(1,795)	(5,894)
(c) advertising and marketing		
(d) leased assets		
(e) staff costs (including directors fees)	(1,123)	(2,498)
(f) administration and corporate costs	(561)	(2,103)
1.3 Dividends received (see note 3)		
1.4 Interest received	3	28
1.5 Interest and other costs of finance paid		
1.6 Income taxes paid		
1.7 Government grants and tax incentives		
1.8 Other (provide details if material)		
1.9 Net cash from / (used in) operating activities	(970)	(3,285)
2. Cash flows from investing activities		
2.1 Payments to acquire:		
(a) entities		
(b) businesses		
(c) property, plant and equipment	(87)	(97)
(d) investments		
(e) intellectual property		
(f) other non-current assets		

Consolidated statement of cash flows	Current quarter \$A'000	Year to date (9 months) \$A'000
2.2 Proceeds from disposal of:		
(a) entities		
(b) businesses		
(c) property, plant and equipment		
(d) investments		
(e) intellectual property		
(f) other non-current assets		
2.3 Cash flows from loans to other entities		
2.4 Dividends received (see note 3)		
2.5 Other (provide details if material) cash on acquisition of subsidiary		
2.6 Net cash from / (used in) investing activities	(87)	(97)
3. Cash flows from financing activities		
3.1 Proceeds from issues of equity securities (excluding convertible debt securities)		
3.2 Proceeds from issue of convertible debt securities		
3.3 Proceeds from exercise of options		
3.4 Transaction costs related to issues of equity securities or convertible debt securities		
3.5 Proceeds from borrowings		
3.6 Loan to Breathe Life Sciences		
3.7 Transaction costs related to loans and borrowings		
3.8 Dividends paid		
3.9 Other – funds for capital raise received in advance of share issue	307	307
3.10 Net cash from / (used in) financing activities	307	307
4. Net increase / (decrease) in cash and cash equivalents for the period		
4.1 Cash and cash equivalents at beginning of period	1,525	3,846
4.2 Net cash from / (used in) operating activities (item 1.9 above)	(970)	(3,285)

Consolidated statement of cash flows		Current quarter \$A'000	Year to date (9 months) \$A'000
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(87)	(97)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	307	307
4.5	Effect of movement in exchange rates on cash held	(26)	(22)
4.6	Cash and cash equivalents at end of period	749	749

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter \$A'000	Previous quarter \$A'000
5.1	Bank balances	548	1,298
5.2	Call deposits	201	227
5.3	Bank overdrafts		
5.4	Other (provide details)		
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	749	1,525

6. Payments to related parties of the entity and their associates

- 6.1 Aggregate amount of payments to related parties and their associates included in item 1
- 6.2 Aggregate amount of payments to related parties and their associates included in item 2

Current quarter \$A'000
157

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments

7. Financing facilities <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	Total facility amount at quarter end \$A'000	Amount drawn at quarter end \$A'000
7.1 Loan facilities		
7.2 Credit standby arrangements		
7.3 Other (please specify) – committed placement April 2024	1,450	
7.4 Total financing facilities	1,450	

7.5 **Unused financing facilities available at quarter end**

7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.

The Company raised \$1.45 million in April 2024

8. Estimated cash available for future operating activities	\$A'000
8.1 Net cash from / (used in) operating activities (Item 1.9)	(970)
8.2 Cash and cash equivalents at quarter end (Item 4.6)	749
8.3 Unused finance facilities available at quarter end (Item 7.5)	
8.4 Total available funding (Item 8.2 + Item 8.3)	
8.5 Estimated quarters of funding available (Item 8.4 divided by Item 8.1)	0.8

Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.

8.6 If Item 8.5 is less than 2 quarters, please provide answers to the following questions:

1. Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?

Revenue lower than average in the quarter, and should improve following TGA approval of medicinal cannabis manufacturing licence. Additional costs incurred in the period in setting up manufacturing facility.

2. Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?

The Company undertook a capital raise post quarter end raising \$1.45 million.

3. Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?

Yes, the business has been further strengthened with the grant of the medicinal cannabis manufacturing licence in Australia. The Company has incurred costs in quarter in achieving the licence and in setting up the manufacturing facility. Additional working capital is required to fund growth in the business, and has been satisfied by the capital raise – see 2 above.

Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date: 30 April 2024.....

Authorised by: ..The Board.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.